# Top 10 intervention extracts from lijecnicki vjesnik-139-365_cleaned.json

=== Ranked Intervention 1 (Extract #24, Therapy) — Score: 11 ===
atients who are nonprogressive after two cycles of
adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in non small-cell lung cancer. J Clin
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-sm

=== Ranked Intervention 2 (Extract #6, Treatment) — Score: 9 ===
rapy
therapy in locally advanced non-small-cell lung cancer: Groupe Lyon-
for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol
Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-
Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7.
37. Sandler A, Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol-
16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi-
ogy in Eastern Cooperative Group Study E4599 of bevacizumab with
tant versus sequential radiochemotherapy in locally advanced non-
paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho-

=== Ranked Intervention 3 (Extract #8, Treatment) — Score: 9 ===
ell lung cancer. J Clin
stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9.
results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che-
Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced
22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a
vinorelbine plus cisplatin compared with observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2

=== Ranked Intervention 4 (Extract #12, Treatment) — Score: 9 ===
i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6.
pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma kinase-positive non-
1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9.
58. Nagano T, Kim YH, Goto K i sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously
lapsed non-small-cell lung cancer.

=== Ranked Intervention 5 (Extract #28, Therapy) — Score: 9 ===
nd Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:
31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94.
therapy regimens for advanced non-small-cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo-
Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77.
55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Ritt

=== Ranked Intervention 6 (Extract #5, Treatment) — Score: 8 ===
arinis F, Dediu M i sur. PARAMOUNT: final overall
versus sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of maintenance pemetrexed ver-
mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed
lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J
14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902.
chemoradiation for stage III non-small cell lung cancer: randomized 35.

=== Ranked Intervention 7 (Extract #9, Treatment) — Score: 8 ===
2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10):
24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin
46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst-
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin
line treatment for patients with advanced EGFR mutation-positive
Oncol 2008;26:3552–9.
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel
open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):
plus carboplatin compared wi

=== Ranked Intervention 8 (Extract #10, Treatment) — Score: 8 ===
itabine in advanced non-
study of two cisplatin-based regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J
in advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52.
pean Organization for Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:
31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94.
therapy regi

=== Ranked Intervention 9 (Extract #11, Treatment) — Score: 8 ===
T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40.
cancer previously treated with platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for
Oncol 2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer
57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6.
pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA app

=== Ranked Intervention 10 (Extract #13, Treatment) — Score: 8 ===
d 2005;353:
59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32.
sus docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the
small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da-
domised controlled trial. Lancet 2014;15:143–55. tabase Syst Rev 2012;4:CD003869.
60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa-
Advanced Non

